Find out how antibody-drug conjugates (ADCs) are advancing cancer treatment by optimising dosing strategies and minimising ...

JSKN033-102 is an open-label, multicenter, Phase Ⅰ/Ⅱ clinical study designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and anti-tumor activity of JSKN033 in patients with ...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that Adcendo ApS ...

China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has approved Alphamab Oncology’s ...

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results for the ADC last month. The Boston biotech is ...

Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that Adcendo ApS ("Adcendo"), a biotech company focused on the ...

Adcendo exercises its option to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need This collaboration further validates ...